GeoVax Secures Multi-Year U.S. Government Contract Extensions for Orthopox Vaccines
GOVX•GeoVax announced that the U.S. government has renewed its funding commitment for orthopox vaccine development, reinforcing support for its Modified Vaccinia Ankara platform under federal preparedness programs. The company cited multi-year contract extensions and strategic stockpile provisions as validation of its long-term smallpox and mpox vaccine readiness.
1. U.S. Government Funding Renewal
GeoVax announced that federal agencies have extended funding agreements through 2028, supporting ongoing development and stockpiling of its Modified Vaccinia Ankara orthopox vaccine candidates for smallpox and mpox preparedness.
2. Contract Details
The multi-year extensions include procurement provisions under the Biomedical Advanced Research and Development Authority (BARDA) that earmark doses for the Strategic National Stockpile and potential follow-on orders based on program milestones.
3. Platform Validation
Company executives highlighted that sustained federal support validates the MVA platform’s safety and immunogenicity profile, bolstering GeoVax’s position in biodefense and pandemic preparedness markets.
4. Financial and Operational Impact
The added contract revenue is expected to fund key clinical and manufacturing activities through 2027, extending GeoVax’s cash runway and positioning the company for future commercial awards.
